Skip to main content

Barclays Sticks to Their Buy Rating for Henry Schein (HSIC)

Tipranks - Tipranks - Thu Feb 26, 4:04AM CST

Barclays analyst Glen Santangelo maintained a Buy rating on Henry Schein today and set a price target of $86.00.

Claim 50% Off TipRanks Premium

Santangelo covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, McKesson, and Cencora. According to TipRanks, Santangelo has an average return of 5.2% and a 51.70% success rate on recommended stocks.

In addition to Barclays, Henry Schein also received a Buy from Evercore ISI’s Elizabeth Anderson CFA in a report issued yesterday. However, on the same day, William Blair maintained a Hold rating on Henry Schein (NASDAQ: HSIC).

See the top stocks recommended by analysts >>

Based on Henry Schein’s latest earnings release for the quarter ending September 27, the company reported a quarterly revenue of $3.34 billion and a net profit of $101 million. In comparison, last year the company earned a revenue of $3.17 billion and had a net profit of $99 million

Read More on HSIC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).